Heusser K, Schobel H P, Adamidis A, Fischer T, Frank H
Human Cardiovascular Physiology Laboratory, Medical Clinic IV, Department of Internal Medicine, University of Erlangen-Nuremberg, Erlangen, Germany.
Kidney Blood Press Res. 2002;25(1):34-41. doi: 10.1159/000049433.
Celiprolol, a newer beta-blocking agent, has been reported to have vasodilatory capacity which may be due to partial beta-2-receptor agonistic activity or to alpha-receptor antagonistic or central sympathoinhibitory effects.
To more critically assess the physiologic effects of celiprolol, we measured sympathetic nerve activity to muscle (MSNA), forearm blood flow (FBF), blood pressure (BP), central venous pressure, and heart rate (HR) in 10 normal volunteers at rest, during unloading of cardiopulmonary baroreceptors with lower body negative pressure (LBNP), and during a cold pressor test (CPT). Responses were compared with those seen with metoprolol and with placebo, i.e. each subject was studied three times.
Celiprolol did not alter resting levels of hemodynamics, FBF, and MSNA nor did it alter responses to LBNP or the CPT. In contrast, metoprolol produced significant decreases of FBF and HR, and increases of forearm vascular resistance and BP, but had also no effect on responses to the applied stress tests.
The lack of peripheral vasoconstriction seen after acute administration of celiprolol is most likely due to its partial beta-2-receptor agonistic effect and does not seem to be due to a central or reflex action or to an alpha-blocking effect. Both beta-blockers do not impair fundamental neural mechanisms involved in circulatory homeostasis.
塞利洛尔是一种新型β受体阻滞剂,据报道具有血管舒张能力,这可能归因于其部分β2受体激动活性、α受体拮抗作用或中枢交感神经抑制作用。
为了更严格地评估塞利洛尔的生理效应,我们在10名正常志愿者静息状态下、采用下体负压(LBNP)卸载心肺压力感受器期间以及冷加压试验(CPT)期间,测量了其肌肉交感神经活动(MSNA)、前臂血流量(FBF)、血压(BP)、中心静脉压和心率(HR)。将这些反应与美托洛尔和安慰剂的反应进行比较,即对每个受试者进行三次研究。
塞利洛尔未改变静息状态下的血流动力学、FBF和MSNA水平,也未改变对LBNP或CPT的反应。相比之下,美托洛尔使FBF和HR显著降低,前臂血管阻力和BP升高,但对施加的应激试验反应也无影响。
急性给予塞利洛尔后未见外周血管收缩,这很可能归因于其部分β2受体激动作用,似乎并非由于中枢或反射作用或α阻滞效应。两种β受体阻滞剂均未损害参与循环稳态的基本神经机制。